Synklino

📍 Copenhagen N, Denmark🗓 Founded 2017👥 28 employees💰 Last funded Sep 2022
Biotechnology Research🌐 synklino.com
Website LinkedIn
Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality. Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.
3
Total investors
0
Early stage
3
Mid stage
0
Late stage
2017
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
3
Investor activity2021–2022 · investors recorded per year
2021220221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Synklino?
Synklino has 3 investors on record on gritt.io, 3 mid-stage.
When did Synklino last raise funding?
The most recent investment in Synklino recorded on gritt.io was in September 2022.
When was Synklino founded?
Synklino was founded in 2017.
What industry is Synklino in?
Synklino operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Synklino based?
Synklino is headquartered in Copenhagen N, Denmark.